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Wild-type p53 is normally expressed at low levels and 
inactive due to the action of MDM2, an E3 ubiquitin 
ligase that binds p53 and promotes its degradation [1, 
2].  However, p53 is stabilized in response to various 
stresses, such as DNA damage or inappropriate 
oncogene signaling, that might otherwise predispose a 
normal cell toward tumorigenesis [3].  The stress-
induced stabilization of p53 results from disruption of 
p53-MDM2 binding.  The majority of stabilized p53 
accumulates in the nucleus where it functions as a 
transcription factor, activating expression of genes that 
induce either apoptosis or cell cycle arrests that can be 
either transient (quiescence) or permanent (senescence).  
Thus, p53 eliminates cells with potentially cancer-
promoting lesions by inhibiting their growth or causing 
them to die.  mTOR is a cytoplasmic kinase whose 
activity is often elevated in cancer [4].  mTOR converts 
signals from activated growth factor receptors into 
downstream events that promote cell proliferation and 
survival.  Previous studies have demonstrated cross-talk 
between the p53 and mTOR signaling pathways.  For 
example, p53 can activate expression of several genes, 
including TSC2, PTEN, IGF-BP3, and others, whose 
protein products can directly or indirectly inhibit mTOR 
activity [5].  These observations make sense given that 
p53 is a tumor suppressor and mTOR has more an 
oncogenic role in promoting cancer cell survival and 
proliferation.  However, more recent studies indicate 
that the outcome of mTOR signaling can be context-
dependent.  Thus, while mTOR signaling promotes 
proliferation and survival under normal conditions, 
mTOR signaling can promote senescence under 
conditions in which the cell cycle is blocked [6, 7].   
These observations support mTOR as a hub for receipt 
of multiple inputs that ultimately determine cell fate.   
When conditions are favorable mTOR activation 
promotes proliferation and survival, however, in the 
context of conflicting signals (e.g. growth factor 
signaling vs.  cell cycle arrest),   the  effect   of    mTOR  
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activation is permanent cell cycle exit (senescence).   
P21 is a cyclin-cdk inhibitor, transcriptional target of 
p53, and potent inducer of senescence [8, 9].   
Blagosklonny and colleagues noted that in some cases 
p53 induction did not induce senescence while ectopic 
expression of p21 did [10].  This led to them to question 
the role of p53 in the senescence program, and whether 
p53 may actively suppress senescence.  To address this, 
they used a cell line in which p21 was expressed from 
an inducible (IPTG-driven) promoter [11].  In this cell 
line, transient p21 expression induced by IPTG caused 
the cells to undergo a senescent arrest characterized by 
flat-cell phenotype, expression of senescence-associated 
beta galactosidase, and a complete loss of proliferative 
potential after IPTG removal [12].  To test the effect of 
p53 on this senescent arrest, the authors first induced 
p21 by IPTG, and then induced p53 expression in the 
same cells by addition of Nutlin-3a, a small molecule 
MDM2 antagonist and potent p53 stabilizer.   
Remarkably, cells in which p53 was induced by Nutlin-
3a were able to resume cycling and fully recover after 
IPTG removal.  These results indicated that p53 
expression converted the senescence response in these 
cells to quiescence.  The suppression of senescence they 
observed was associated with p53-dependent inhibition 
of mTOR activity (12).  In the current issue of Aging, 
Korotchkina et al. [13] demonstrate that shRNA-
mediated knockdown of TSC2, a negative regulator of 
mTOR and p53 target gene [5], imposed senescence in 
these Nutlin-3a treated cells.  The results support a 
model in which p53 can suppress senescence through 
upregulation of TSC2 and inhibition of mTOR. 
 
Our lab has also examined responses to p53 activation 
by Nutlin-3a.  Our original report demonstrated that 
Nutlin-3a promoted a non-permanent, tetraploid G1-
arrest in two different p53 wild-type cancer cell lines 
(HCT116 and U2OS).  Both cell lines underwent 
endoreduplication after Nutlin-3a removal, giving rise 
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apoptosis [14].  More recently, we demonstrated that 
Nutlin-3a could promote a tetraploid G1-arrest in 
multiple p53 wild-type cell lines [15].  However, some 
cell lines underwent endoreduplication to relatively high 
extents after Nutlin-3a removal while other cell lines 
did not.  The resistance to endoreduplication observed 
in some cell lines was associated with a prolonged 4N 
arrest after Nutlin-3a removal.  Knockdown of either 
p53 or p21 immediately after Nutlin-3a removal could 
drive endoreduplication in otherwise resistant 4N cells.  
Finally, 4N arrested cells had diminished p53 
expression, but retained high levels of p21.  Moreover, 
these cells expressed senescence-associated beta 
galactosidase, had a flattened cell phenotype, and 
underwent a permanent proliferation block (senescence) 
after Nutlin-3a removal.  These findings demonstrated 
that transient Nultin-3a treatment can promote 
senescence in 4N cells of certain cell lines associated 
with persistent p21 expression and resistance to 
endoreduplication.  In terms of a model, the results 
suggest p53 is required to initiate Nutlin-3a-induced 
senescence by increasing p21 expression, but is not 
required to maintain senescence.  In light of the findings 
by Blagosklonny and colleagues, we would speculate 
that the diminished level of p53 restores mTOR activity 
in these 4N cells, and that mTOR activity, as well as 
elevated p21, are required for their senescent arrest. 
 
Implications / Questions 
 
The findings of Blagosklonny and colleagues have 
obvious clinical implications, particularly regarding the 
use of Nutlin-3a or other MDM2 antagonists in cancer 
therapy.  Nutlin-3a is in preclinical stages of develop-
ment and has tremendous potential as a therapeutic 
agent against p53 wild-type cancers.  Indeed, Nutlin-3a 
treatment inhibited the growth of multiple p53 wild-
type human tumor cell lines grown as xenografts in 
nude mice [16, 17], and Nutlin-3a causes a pronounced 
cell cycle arrest or apoptotic response in p53 wild-type 
cancer cell lines [17, 18].  However, if p53 activation by 
Nutlin-3a can suppress senescence in cancer cells and 
cause them to arrest in a quiescent state, then these cells 
could recover after treatment and resume cycling.  This 
would conceivably limit the effectiveness of Nutlin-3a-
based therapies.  In this issue of Aging it was reported 
that the status of the mTOR pathway can determine, at 
least in part, the choice between senescence and 
quiescence in Nutlin-3a and p53-arrested cells [13].  In 
fact, Nutlin-3a failed to inhibit mTOR in melanoma-
derived cell lines and mouse embryo fibroblasts that 
undergo senescence as their primary response to p53 
activation.  The findings imply that Nutlin-3a could be 
effective as a single treatment agent, but only against 
cancers in which p53 fails to inhibit or only partially 
inhibits mTOR.  Studies to determine the molecular 
basis for why p53 can inhibit mTOR in some cell lines 
but not others will be closely watched. 
 
Nutlin-3a stabilizes p53 in a non-genotoxic fashion 
without inducing DNA damage [19], and a question that 
arises is the extent to which the findings of 
Blagosklonny’s group can be generalized to the p53 
stress response.  The stabilization and activation of p53 
in response to DNA damaging stress result from post-
translational modifications (phosphorylations) in p53 
and MDM2 that disrupt their interaction [3].  These 
same modifications can also influence promoter 
selectivity, thus directing p53 to different target genes 
[20, 21].  DNA damage can also activate signaling 
pathways independent of p53 that influence transcript-
tion, DNA repair, etc.  Blagosklonny and  colleagues 
increased p53 expression through mostly non-genotoxic 
mechanisms (Nutlin-3a treatment, Ad-p53 infection) 
and showed this p53 could suppress senescence through 
mTOR inhibition [6, 7, 12].  It remains to be seen the 
extent to which p53 induction in the context of a larger 
DNA damage response similarly suppresses senescence.  
On a related note, Nutlin-3a has also been considered as 
a combinatorial agent for therapy with DNA damaging 
chemotherapeutic drugs.  Thus, it will be important to 
clarify the extent to which p53 induced by combination 
Nutlin plus DNA damaging stress suppresses 
senescence. 
 
A final question is why p53 would suppress senescence 
and favor quiescence.  A quiescent-like arrest mediated 
by p53 has been well described.  In response to low 
levels of DNA damage p53 induces transient G1 and 
G2-phase arrests that allow cells time to repair their 
DNA [22].  Once DNA repair is complete, cells can 
resume entry into S-phase and mitosis.  In this context, 
quiescence allows the cells to recover from whatever 
stress is inducing p53.  Blagosklonny and colleagues 
showed p53 induction by Nutlin-3a suppressed 
senescence and favored quiescence, suggesting p53 was 
functioning in a way to allow stress recovery.  Again, 
since Nutlin-3a induces p53 in a non-genotoxic fashion, 
it would be interesting to know whether this is a 
property specific to p53 induced by non-genotoxic 
means or, in the case of low level DNA damage, 
whether it is a property of p53 molecules that have not 
been subject to damage-induced modifications. 
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